top of page
Search
Illustrative image of surgical operating room and financial results

J&J Q3 2026: Surgery Sales Edge Lower Amid Portfolio Restructuring

Oct 19
1 min read

October 13, 2026 — Johnson & Johnson reported third-quarter 2026 results, with group sales of $25.399 billion, an increase of 5.9% year over year.

The MedTech business recorded quarterly sales of approximately $8.642 billion. Surgery sales totaled approximately $2.528 billion, down 0.6% from the prior-year period, according to the company's quarterly financial disclosures.

Johnson & Johnson has continued a restructuring initiative within its Surgery business, including plans to exit selected non-strategic product lines and optimize parts of its operating footprint. The company has not identified specific suture products as discontinued in the disclosures cited here.

These figures refer to company and business segments, not standalone Ethicon surgical suture revenue.

Source: Johnson & Johnson, Third-Quarter 2026 Results, October 13, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2026-results-raises-2026-guidance

Image: original illustrative rendering of surgical sutures and financial performance; not a photograph of any named company's products.

 
 
 

Comments


©2022 by MATRIXLabs Medical Inc. All Rights Reserved.

bottom of page